CVS Health (CVS) has just outlined its latest priorities to investors at the Wells Fargo 21st Annual Healthcare Conference in Boston, spotlighting its mix of retail pharmacy, insurance and health services at a time of muted growth expectations.
Despite slower trading in recent weeks, with a 90 day share price return that is down 5.1%, CVS Health has delivered a 19.0% year to date share price gain and a 1 year total shareholder return of 33.0%. This suggests momentum has been rebuilding over a longer stretch as investors weigh conference updates alongside new vaccine and community health initiatives.
Scan how CVS Health compares with other large healthcare players by reviewing the hand picked list of solid balance sheet and fundamentals (24 results).
After a 33.0% total return over the past year and fresh conference buzz, CVS Health now sits at an interesting crossroads. Is the bigger opportunity still in front of you, or has most of the upside already played out in the current valuation?
Most Popular Narrative: 17% Undervalued
CVS Health closed at $95.38, while the most followed narrative pegs fair value at $114.88, using a 7.5% discount rate to frame that gap.
Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities, supporting long-term operating margin and earnings growth as margin recovery initiatives gain traction.
Read the complete narrative. Read the complete narrative.
Want to see what underpins that valuation call for CVS Health? The narrative focuses on improving profitability, compounding revenue and a future earnings multiple that assumes meaningful execution. Curious which exact earnings path and margin rebuild need to line up for that fair value to make sense?
Result: Fair Value of $114.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the bullish CVS Health narrative can fray if medical benefit ratios stay elevated for longer than expected or if pharmacy reimbursement pressure continues to squeeze profitability across key segments.
Find out about the key risks to this CVS Health narrative.
Another View On CVS Health’s Valuation
The first narrative leans on earnings forecasts and a fair value of $114.88 for CVS Health. A different lens comes from our DCF model, which prices future cash flows at $277.75 per share. That is a very wide gap. Does it signal mispricing, or just very demanding cash flow assumptions?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed messages in the CVS Health story today. If you want to move quickly and rely on your own judgement, weigh up the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond CVS Health?
If CVS Health has your attention, do not stop there. Broaden your watchlist with a few focused screens that target different types of opportunities.
Use the Simply Wall St Screener to uncover other stocks and investment angles that could round out your portfolio and keep you ahead of the crowd.
- Target long term compounding potential by scanning a curated pool of quality companies trading below estimated fair value through the 31 high quality undervalued stocks.
- Steady your portfolio with businesses that prioritise resilience and financial strength by reviewing the 10 resilient stocks with low risk scores.
- Hunt for potential future leaders in corners of the market that are not crowded yet by checking the 17 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com